Combination drug therapy before surgery for early-stage HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two targeted drugs given before surgery to shrink HER2-positive breast cancer. It may help make surgery more successful and reduce the chance of the cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 70.
- You have been diagnosed with early or locally advanced breast cancer that is HER2-positive and hormone receptor-positive.
- You have not had any prior cancer treatment, such as chemotherapy, radiation, or hormone therapy.
- Your cancer is stage II or III and has not spread to distant parts of the body.
- You are generally healthy and able to perform daily activities (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
This trial tests a new drug (SHR-A1811) alone or with letrozole given before surgery to shrink early-stage breast cancer that is hormone receptor-positive and HER2-low. It may help make surgery more effective.
This trial tests a new drug, SHR-A1811, given alone or followed by a standard treatment, before surgery for early-stage HER2-positive breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This study tests whether giving two drugs (SHR-A1811 and pertuzumab) before surgery can shrink HER2-positive breast cancer tumors. It aims to see if this combination improves treatment outcomes for patients with stage II or III disease.
This trial tests a combination of three HER2-targeted drugs with a CDK4/6 inhibitor before surgery for breast cancer that is both HER2-positive and ER-positive. It aims to see if this approach shrinks tumors more effectively and is safe.
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.